| LBCTR2019010167 | CNTO1959CRD3001 | A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease | A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease | Interventional | Complete | 24/10/2018 |
| LBCTR2019030200 | RTH258B2302 | A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema | A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema | Interventional | Complete | 20/02/2019 |
| LBCTR2022055033 | CMBG453B12203 | A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants | A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria | Interventional | Suspended | 21/04/2022 |
| LBCTR2020124661 | 56021927PCR3015 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | Interventional | Pending | 06/11/2020 |
| LBCTR2022034916 | AG348-C-020 | A Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease (SCD) | A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease | Interventional | Pending | 08/11/2021 |
| LBCTR2022014845 | AG348-C-018 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (ENERGIZE-T). | A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) | Interventional | Pending | 15/07/2021 |
| LBCTR2022014844 | AG348-C-017 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) | A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) | Interventional | Pending | 15/07/2021 |
| LBCTR2020114568 | APD334-202 | A Study Evaluating the Efficacy and Safety of Etrasimod in the Treatment of Patients With Moderately to Severely Active Crohn's Disease | A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease | Interventional | Recruiting | 26/08/2020 |
| LBCTR2022105085 | MX39897 | A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORS PROFILED WITH A NEXT-GENERATION SEQUENCING TEST (WAYFIND-R) | A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORS PROFILED WITH A NEXT-GENERATION SEQUENCING TEST (WAYFIND-R) | Observational | Pending | 25/06/2022 |
| LBCTR2019091283 | C1701-202 | A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease | A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease | Interventional | Complete | 12/09/2019 |